As Chairman of the EVER Pharma Group, Dr. Friedrich Hillebrand brings over 40 years of pharmaceutical experience covering development, production and commercialization. He was until 2009 CEO of EBEWE Pharma, a business specializing in oncology and neurology, that he led and grew for 30 years until finally selling to Novartis. Friedrich holds a PhD in Chemical Engineering from the University of Vienna.
Georges Kahwati is General Manager of EVER Neuro Pharma, EVER Valinject and EVER Pharma Jena. He joined the EVER Pharma Group from Sandoz International where he held roles of Global Head Commercial Operations (Oncology Injectables) and General Manager of the Sandoz Unterach site covering Technical Operations, Quality and Development. Prior to Sandoz, Georges was VP Speciality Injectables at EBEWE Pharma and significantly grew the oncology franchise to be a market leader prior to the sale of the business to Novartis in 2009. Georges holds a Bachelor of Commerce from McGill University and an MBA from INSEAD.
Dr. Wolfgang Schmitzberger has been with the EBEWE/EVER Group since 1992. For many years he was the Site Head at EBEWE‘s Austrian headquarters and responsible for Production, Quality, Engineering, Supply Chain, Contract Manufacturing and Approval/Licensing. Today he oversees EVER Technical Operations in Austria and Germany. Wolfgang holds a PhD in Technical Chemistry and Economics from the University of Linz.
From 2013 Dr. Julia Hillebrand served as head of Corporate Development at EVER Pharma and since 2016 has headed the Neurology business division. She is also a member of the EVER Pharma Management Board. Julia is a medical doctor graduate of the Medical University of Vienna.